

Alessandra Longhi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/817365/publications.pdf>

Version: 2024-02-01

94
papers

6,296
citations

76196

40
h-index

66788

78
g-index

94
all docs

94
docs citations

94
times ranked

5135
citing authors

#	ARTICLE	IF	CITATIONS
1	Primary bone osteosarcoma in the pediatric age: State of the art. <i>Cancer Treatment Reviews</i> , 2006, 32, 423-436.	3.4	562
2	Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy. <i>Cancer</i> , 2006, 106, 1154-1161.	2.0	502
3	Neoadjuvant Chemotherapy With High-Dose Ifosfamide, High-Dose Methotrexate, Cisplatin, and Doxorubicin for Patients With Localized Osteosarcoma of the Extremity: A Joint Study by the Italian and Scandinavian Sarcoma Groups. <i>Journal of Clinical Oncology</i> , 2005, 23, 8845-8852.	0.8	394
4	Long-Term Outcome for Patients With Nonmetastatic Osteosarcoma of the Extremity Treated at the Istituto Ortopedico Rizzoli According to the Istituto Ortopedico Rizzoli/Osteosarcoma-2 Protocol: An Updated Report. <i>Journal of Clinical Oncology</i> , 2000, 18, 4016-4027.	0.8	385
5	Prognostic Factors in Nonmetastatic Ewing's Sarcoma of Bone Treated With Adjuvant Chemotherapy: Analysis of 359 Patients at the Istituto Ortopedico Rizzoli. <i>Journal of Clinical Oncology</i> , 2000, 18, 4-4.	0.8	309
6	Giant cell tumor of the extremity: A review of 349 cases from a single institution. <i>Cancer Treatment Reviews</i> , 2010, 36, 1-7.	3.4	296
7	Phase II Study of Imatinib in Advanced Chordoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 914-920.	0.8	230
8	Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity. <i>Cancer</i> , 2003, 97, 3068-3075.	2.0	211
9	Short, Full-Dose Adjuvant Chemotherapy in High-Risk Adult Soft Tissue Sarcomas: A Randomized Clinical Trial From the Italian Sarcoma Group and the Spanish Sarcoma Group. <i>Journal of Clinical Oncology</i> , 2012, 30, 850-856.	0.8	156
10	Prognostic factors in non-metastatic Ewing's sarcoma tumor of bone: An analysis of 579 patients treated at a single institution with adjuvant or neoadjuvant chemotherapy between 1972 and 1998. <i>Acta Oncologica</i> , 2006, 45, 469-475.	0.8	137
11	Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy. <i>European Journal of Cancer</i> , 2005, 41, 2836-2845.	1.3	127
12	Local recurrence and local control of non-metastatic osteosarcoma of the extremities: A 27-year experience in a single institution. <i>Journal of Surgical Oncology</i> , 2007, 96, 118-123.	0.8	126
13	Treatment and outcome of recurrent osteosarcoma: Experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy. <i>Acta Oncologica</i> , 2005, 44, 748-755.	0.8	124
14	Grade of chemotherapy-induced necrosis as a predictor of local and systemic control in 881 patients with non-metastatic osteosarcoma of the extremities treated with neoadjuvant chemotherapy in a single institution. <i>European Journal of Cancer</i> , 2005, 41, 2079-2085.	1.3	115
15	Nonmetastatic osteosarcoma of the extremity with pathologic fracture at presentation: Local and systemic control by amputation or limb salvage after preoperative chemotherapy. <i>Acta Orthopaedica</i> , 2003, 74, 449-454.	1.4	103
16	Insulin Receptor Isoform A and Insulin-like Growth Factor II as Additional Treatment Targets in Human Osteosarcoma. <i>Cancer Research</i> , 2009, 69, 2443-2452.	0.4	96
17	Late effects of chemotherapy and radiotherapy in osteosarcoma and Ewing sarcoma patients. <i>Cancer</i> , 2012, 118, 5050-5059.	2.0	93
18	The role of surgical margins in treatment of Ewing's sarcoma family tumors: Experience of a single institution with 512 patients treated with adjuvant and neoadjuvant chemotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 766-772.	0.4	92

#	ARTICLE	IF	CITATIONS
19	Osteosarcoma in Patients Older Than 65 Years. <i>Journal of Clinical Oncology</i> , 2008, 26, 5368-5373.	0.8	91
20	EURO-B.O.S.S.: A European study on chemotherapy in bone-sarcoma patients aged over 40: Outcome in primary high-grade osteosarcoma. <i>Tumori</i> , 2018, 104, 30-36.	0.6	84
21	Long-term follow-up of patients with doxorubicin-induced cardiac toxicity after chemotherapy for osteosarcoma. <i>Anti-Cancer Drugs</i> , 2007, 18, 737-744.	0.7	83
22	Fertility in Male Patients Treated With Neoadjuvant Chemotherapy for Osteosarcoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2003, 25, 292-296.	0.3	82
23	Neoadjuvant Chemotherapy for Extremity Osteosarcoma: Preliminary Results of the Rizzoli's 4th Study. <i>Acta Oncologica</i> , 1998, 37, 41-48.	0.8	78
24	Nonmetastatic Osteosarcoma of the Extremity: Results of a Neoadjuvant Chemotherapy Protocol (IOR/OS-3) with High-dose Methotrexate, Intraarterial or Intravenous Cisplatin, Doxorubicin, and Salvage Chemotherapy Based on Histologic Tumor Response. <i>Tumori</i> , 1999, 85, 458-464.	0.6	71
25	Height as a Risk Factor for Osteosarcoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2005, 27, 314-318.	0.3	70
26	Neoadjuvant Chemotherapy for Osteosarcoma of the Extremity. <i>Journal of Pediatric Hematology/Oncology</i> , 2003, 25, 845-853.	0.3	63
27	Adjuvant and neoadjuvant chemotherapy for Ewing sarcoma family tumors in patients aged between 40 and 60. <i>Cancer</i> , 2007, 109, 780-786.	2.0	62
28	Influence of local recurrence on survival in patients with extremity osteosarcoma treated with neoadjuvant chemotherapy. <i>Cancer</i> , 2006, 106, 2701-2706.	2.0	61
29	Periosteal osteosarcoma. <i>Cancer</i> , 2011, 117, 1731-1735.	2.0	60
30	Palliative therapy for osteosarcoma. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 217-227.	1.1	58
31	Treatment of nonmetastatic Ewing's sarcoma family tumors of the spine and sacrum: the experience from a single institution. <i>European Spine Journal</i> , 2009, 18, 1091-1095.	1.0	54
32	Multimodal Therapy for the Treatment of Nonmetastatic Ewing Sarcoma of Pelvis. <i>Journal of Pediatric Hematology/Oncology</i> , 2003, 25, 118-124.	0.3	53
33	Pazopanib in relapsed osteosarcoma patients: report on 15 cases. <i>Acta Oncologica</i> , 2019, 58, 124-128.	0.8	50
34	Role of surgery in local treatment of Ewing's sarcoma of the extremities in patients undergoing adjuvant and neoadjuvant chemotherapy. <i>Oncology Reports</i> , 2004, 11, 111-20.	1.2	50
35	Second Malignancy in 597 Patients With Ewing Sarcoma of Bone Treated at a Single Institution With Adjuvant and Neoadjuvant Chemotherapy Between 1972 and 1999. <i>Journal of Pediatric Hematology/Oncology</i> , 2005, 27, 517-520.	0.3	49
36	Bone metastases in osteosarcoma patients treated with neoadjuvant or adjuvant chemotherapy The Rizzoli experience in 52 patients. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2006, 77, 938-943.	1.2	49

#	ARTICLE	IF	CITATIONS
37	Histologic Response of High-Grade Nonmetastatic Osteosarcoma of the Extremity to Chemotherapy. <i>Clinical Orthopaedics and Related Research</i> , 2001, 386, 186-196.	0.7	48
38	Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2617-2624.	2.0	45
39	Prognostic significance of serum alkaline phosphatase in osteosarcoma of the extremity treated with neoadjuvant chemotherapy: recent experience at Rizzoli Institute. <i>Oncology Reports</i> , 2002, 9, 171-5.	1.2	45
40	Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1. <i>Oncotarget</i> , 2017, 8, 111836-111846.	0.8	44
41	Primary High-Grade Osteosarcoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2005, 27, 129-134.	0.3	42
42	Denosumab in patients with aneurysmal bone cysts: A case series with preliminary results. <i>Tumori</i> , 2018, 104, 344-351.	0.6	41
43	Increased osteoclast activity is associated with aggressiveness of osteosarcoma. <i>International Journal of Oncology</i> , 2008, 33, 1231-8.	1.4	39
44	Second Malignant Neoplasm in Patients With Osteosarcoma of the Extremities Treated With Adjuvant and Neoadjuvant Chemotherapy. <i>Journal of Pediatric Hematology/Oncology</i> , 2006, 28, 774-780.	0.3	38
45	High-Grade Osteosarcoma of the Extremity: Differences Between Localized and Metastatic Tumors at Presentation. <i>Journal of Pediatric Hematology/Oncology</i> , 2002, 24, 27-30.	0.3	37
46	Results of the second interim assessment of rEECur, an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES).. <i>Journal of Clinical Oncology</i> , 2020, 38, 11502-11502.	0.8	34
47	Effect of oral contraceptive on ovarian function in young females undergoing neoadjuvant chemotherapy treatment for osteosarcoma. <i>Oncology Reports</i> , 2003, 10, 151-5.	1.2	34
48	Late Relapse in Osteosarcoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2006, 28, 418-422.	0.3	32
49	Reproductive functions in female patients treated with adjuvant and neoadjuvant chemotherapy for localized osteosarcoma of the extremity. <i>Cancer</i> , 2000, 89, 1961-1965.	2.0	31
50	Neoadjuvant chemotherapy for osteosarcoma of the extremities in patients aged 41â€“60 years. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2007, 78, 377-384.	1.2	30
51	Predictive Factors of Histologic Response to Primary Chemotherapy in Patients With Ewing Sarcoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2007, 29, 364-368.	0.3	29
52	Telangiectatic osteosarcoma of the extremity: Neoadjuvant chemotherapy in 24 cases. <i>Acta Orthopaedica</i> , 2001, 72, 167-172.	1.4	27
53	The role of 18F-FDG PET/CT in soft tissue sarcoma. <i>Nuclear Medicine Communications</i> , 2019, 40, 626-631.	0.5	27
54	Delay in Diagnosis of High-Grade Osteosarcoma of the Extremities. Has it any Effect on the Stage of Disease?. <i>Tumori</i> , 2000, 86, 204-206.	0.6	25

#	ARTICLE	IF	CITATIONS
55	Stereotactic Radiotherapy in the Treatment of Lung Metastases from Bone and Soft-tissue Sarcomas. <i>Anticancer Research</i> , 2015, 35, 5581-6.	0.5	24
56	A Randomized Study on Postrelapse Disease-Free Survival with Adjuvant Mistletoe versus Oral Etoposide in Osteosarcoma Patients. <i>Evidence-based Complementary and Alternative Medicine</i> , 2014, 2014, 1-9.	0.5	22
57	Relationship between dose-intensity of treatment and outcome for patients with osteosarcoma of the extremity treated with neoadjuvant chemotherapy. <i>Oncology Reports</i> , 2001, 8, 883-8.	1.2	22
58	Pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor: safety and efficacy. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 441-445.	1.1	20
59	Predictive Factors of Histological Response to Primary Chemotherapy in Ewing's Sarcoma. <i>Acta Oncologica</i> , 1998, 37, 671-676.	0.8	19
60	Neoadjuvant chemotherapy for radioinduced osteosarcoma of the extremity: The Rizzoli experience in 20 cases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 505-511.	0.4	19
61	Non-metastatic osteosarcoma of the extremities in children aged 5 years or younger. <i>Pediatric Blood and Cancer</i> , 2010, 55, 652-654.	0.8	19
62	Is there a role for chemotherapy after local relapse in high-grade osteosarcoma?. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27792.	0.8	19
63	Bone marrow biopsy in the initial staging of Ewing sarcoma: Experience from a single institution. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27653.	0.8	19
64	Osteosarcoma follow-up: chest X-ray or computed tomography?. <i>Clinical Sarcoma Research</i> , 2017, 7, 3.	2.3	17
65	Outcome of lung metastases due to bone giant cell tumor initially managed with observation. <i>Journal of Orthopaedic Surgery and Research</i> , 2020, 15, 510.	0.9	17
66	Exploring Metabolic Adaptations to the Acidic Microenvironment of Osteosarcoma Cells Unveils Sphingosine 1-Phosphate as a Valuable Therapeutic Target. <i>Cancers</i> , 2021, 13, 311.	1.7	16
67	Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy. <i>Oncology Reports</i> , 2003, 10, 851-7.	1.2	16
68	Ewing's sarcoma family tumors of the humerus: Outcome of patients treated with radiotherapy, surgery or surgery and adjuvant radiotherapy. <i>Radiotherapy and Oncology</i> , 2009, 93, 383-387.	0.3	15
69	Simultaneous Osteosarcoma Lung Metastasis and Second Primary Lung Cancer. <i>Journal of Pediatric Hematology/Oncology</i> , 2004, 26, 457-461.	0.3	14
70	No correlation between methotrexate serum level and histologic response in the pre-operative treatment of extremity osteosarcoma. <i>Anti-Cancer Drugs</i> , 2006, 17, 411-415.	0.7	14
71	The Release of Inflammatory Mediators from Acid-Stimulated Mesenchymal Stromal Cells Favours Tumour Invasiveness and Metastasis in Osteosarcoma. <i>Cancers</i> , 2021, 13, 5855.	1.7	14
72	Ewing Sarcoma in Patients over 40 Years of Age: A Prospective Analysis of 31 Patients Treated at a Single Institution. <i>Tumori</i> , 2016, 102, 481-487.	0.6	13

#	ARTICLE	IF	CITATIONS
73	Phase 2 study for nonmetastatic extremity high-grade osteosarcoma in pediatric and adolescent and young adult patients with a risk-adapted strategy based on ABCB1/P-glycoprotein expression: An Italian Sarcoma Group trial (ISG/OS-2). <i>Cancer</i> , 2022, 128, 1958-1966.	2.0	12
74	High-Dose Medroxyprogesterone Acetate versus Oophorectomy as First-Line Therapy of Advanced Breast Cancer in Premenopausal Patients. <i>Oncology</i> , 1991, 48, 1-6.	0.9	11
75	A randomized study with adjuvant mistletoe versus oral Etoposide on post relapse disease-free survival in osteosarcoma patients. <i>European Journal of Integrative Medicine</i> , 2009, 1, 27-33.	0.8	9
76	Sinusoidal obstruction syndrome/veno-occlusive disease after high-dose intravenous busulfan/melphalan conditioning therapy in high-risk Ewing Sarcoma. <i>Bone Marrow Transplantation</i> , 2018, 53, 591-599.	1.3	8
77	Reproductive functions in female patients treated with adjuvant and neoadjuvant chemotherapy for localized osteosarcoma of the extremity. <i>Cancer</i> , 2000, 89, 1961-1965.	2.0	6
78	Spontaneous Regression of Lung Metastasis From Osteosarcoma: A Case Report. <i>Journal of Pediatric Hematology/Oncology</i> , 2008, 30, 90-92.	0.3	6
79	Bone Turnover Marker (BTM) Changes after Denosumab in Giant Cell Tumors of Bone (GCTB): A Phase II Trial Correlative Study. <i>Cancers</i> , 2022, 14, 2863.	1.7	6
80	A comment and update on "Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup". <i>European Journal of Cancer</i> , 2003, 39, 548-549.	1.3	5
81	Effect of oral contraceptive on ovarian function in young females undergoing neoadjuvant chemotherapy treatment for osteosarcoma. <i>Oncology Reports</i> , 2003, 10, 151.	1.2	5
82	Long-Term Follow-up of a Randomized Study of Oral Etoposide versus <i>Viscum album</i> Fermentatum Pini as Maintenance Therapy in Osteosarcoma Patients in Complete Surgical Remission after Second Relapse. <i>Sarcoma</i> , 2020, 2020, 1-9.	0.7	5
83	Relative Validity of an Italian EPIC Food Frequency Questionnaire for Dietary Factors in Children and Adolescents. A Rizzoli Orthopedic Institute Study. <i>Nutrients</i> , 2021, 13, 1245.	1.7	5
84	Front-Line Window Therapy with Temozolomide and Irinotecan in Patients with Primary Disseminated Multifocal Ewing Sarcoma: Results of the ISG/AIEOP EW-2 Study. <i>Cancers</i> , 2021, 13, 3046.	1.7	5
85	Histological response to neoadjuvant chemotherapy in localized Ewing sarcoma of the bone: A retrospective analysis of available scoring tools. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1778-1783.	0.5	5
86	The role of chemotherapy in the treatment of bone and soft tissue sarcomas. <i>Orthopaedics and Trauma</i> , 2005, 19, 119-126.	0.3	3
87	Predictors of lung recurrence and disease-specific mortality after pulmonary metastasectomy for soft tissue sarcoma. <i>Surgical Oncology</i> , 2021, 37, 101532.	0.8	3
88	Salivary gland second cancer after bone sarcoma treatment. <i>European Journal of Orthopaedic Surgery and Traumatology</i> , 2015, 25, 1201-1204.	0.6	2
89	Maintenance therapy with oral cyclophosphamide plus celecoxib in patients with metastatic Ewing sarcoma: Results of the Italian Sarcoma Group/AIEOP EW-2 study. <i>Journal of Clinical Oncology</i> , 2020, 38, 10517-10517.	0.8	2
90	Chemosensitivity of Lung Metastatic High-Grade Synovial Sarcoma. <i>Journal of Clinical Medicine</i> , 2021, 10, 5956.	1.0	2

#	ARTICLE	IF	CITATIONS
91	Maternal and Neonatal Outcomes in Pregnancies Complicated by Bone and Soft-Tissue Tumors. <i>Obstetrics and Gynecology</i> , 2005, 105, 447.	1.2	1
92	Long term results in osteosarcoma patients treated with <i>Viscum album Fermentatum P</i> versus Etoposide as maintenance therapy after second relapse. <i>Phytomedicine</i> , 2019, 61, 10-11.	2.3	1
93	Whole Lung Irradiation after High-Dose Busulfan/Melphalan in Ewing Sarcoma with Lung Metastases: An Italian Sarcoma Group and Associazione Italiana Ematologia Oncologia Pediatrica Joint Study. <i>Cancers</i> , 2021, 13, 2789.	1.7	1
94	Advances in treatment for tenosynovial giant cell tumors. <i>Expert Opinion on Orphan Drugs</i> , 2018, 6, 753-757.	0.5	0